Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer (HNC-SYSU-005)
A Pilot Study of Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Sun Yat-sen Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
- Patients underwent NACI before surgery
- Patients accepted the surgery alone.
Description
Inclusion Criteria:
Patients with advanced OSCC who received NACI before surgery
- Confirmation of primary OSCC by two experienced pathologists;
- Clinical stage III/ IVA (cT1-2/cN1-2/M0 or cT3-4a/cN0-2/M0) according to the 8th Edition of American Joint Committee on Cancer (AJCC) guideline;
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;
- No prior anti-cancer therapy;
- Locally resectable advanced tumor evaluated by a head and neck surgeon.
Advanced OSCC patients who only received surgery
- A histopathologic diagnosis of primary OSCC;
- A clinical stage of III/IVA (AJCC, 8th edition);
- An ECOG performance status of 0 to 1.
Exclusion Criteria:
Patients with advanced OSCC who received NACI before surgery
- Patients with other pathological types, without NACI or Surgery;
- Incomplete pre-treatment data;
- Lost to follow up were excluded from the study.
Advanced OSCC patients who only received surgery
- Patients who had received other therapies targeting the head and neck region before the surgery or those with evidence of recurrence or metastasis, as assessed by physical examination reports or imaging studies before surgery
- Lost to follow up.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
neoadjuvant chemoimmunotherapy+surgery
Patients who underwent neoadjuvant chemoimmunotherapy before surgery
|
A comparative evaluation of patient prognosis between those who received neoadjuvant chemoimmunotherapy-surgery treatment and those who underwent surgery alone.
|
|
surgery
Patients who accepted the surgery alone
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease-free survival (DFS)
Time Frame: 2 years
|
DFS(by months) is defined as the time from treatment until the date of the first relapse (local/regional recurrence or distant metastasis) or death (from any cause) whichever comes firsts and regardless of whether the patient withdraws from treatment or receives another anti-cancer therapy prior to disease DFS is defined as the time from treatment until the date of the first relapse (local/regional recurrence or distant metastasis) or death (from any cause) whichever comes firsts and regardless of whether the patient withdraws from treatment or receives another anti-cancer therapy prior to disease relapse.
|
2 years
|
|
Overall survival (OS)
Time Frame: 2 years
|
The time(years) from day 1 of study treatment until death from any cause.
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jinsong Li, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Head and Neck Neoplasms
- Stomatognathic Diseases
- Mouth Diseases
- Mouth Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Carboplatin
- Paclitaxel
- Albumin-Bound Paclitaxel
- Immune Checkpoint Inhibitors
Other Study ID Numbers
Other Study ID Numbers
- SYSKY-2023-184-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.